Edwards Lifesciences reports Q3 adjusted EPS 59c, consensus 59c

Reports Q3 revenue $1.48B, consensus $1.48B. “We are pleased with our strong third quarter performance, which included multiple new therapy approvals for the treatment of patients globally and important achievements on clinical milestones, as well as another quarter of double-digit sales growth,” said Bernard Zovighian, CEO. “The increasing demand for our advanced technologies, coupled with the successful execution of our innovation strategy, gives us confidence in the tremendous opportunity to address unmet patient needs and drive differentiated long-term value.”